Current Report Filing (8-k)
August 21 2018 - 6:58AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported):
July 5, 2018
Humanigen, Inc.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
001-35798
|
|
77-0557236
|
(State or other Jurisdiction of
Incorporation)
|
|
(Commission File No.)
|
|
(IRS Employer Identification No.)
|
533 Airport Boulevard, Suite 400
Burlingame, CA 94005
(Address of principal executive offices,
including zip code)
(650) 243-3100
(Registrant’s telephone number,
including area code)
(Former Name or Former Address, if
Changed Since Last Report)
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
|
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01. Regulation FD Disclosure
Humanigen,
Inc. (the “Company”) intends, from time to time, to present and/or distribute to the investment community and utilize
at various industry and other conferences the slide presentation furnished as Exhibit 99.1 hereto.
This Current
Report on Form 8-K is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the
Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and regardless of any general
incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing. The filing
of this Item 7.01 of this Current Report on Form 8-K shall not be deemed an admission as to the materiality of any information
herein that is required to be disclosed solely by reason of Regulation FD.
Item
9.01.
Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Humanigen, Inc.
|
|
|
|
By:
|
/s/ Cameron Durrant
|
|
|
Name: Cameron Durrant
Title: Chairman
of the Board and Chief Executive Officer
|
|
|
|
Dated: August 21, 2018